default author photo

Satoshi Morita

Kyoto University - Department of Biomedical Statistics and Bioinformatics

Kyoto

Japan

Kyoto University - Institute for Advancement of Clinical and Translational Science

Kyoto

Japan

SCHOLARLY PAPERS

5

DOWNLOADS

413

TOTAL CITATIONS

1

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial

Downloads 210 (362,957)
Citation 1

Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial

Number of pages: 38 Posted: 25 Feb 2019
Hanako Ikeda, Yuki Muraoka, Masayuki Hata, Eriko Sumi, Takafumi Ikeda, Takayuki Nakagawa, Hiroyasu Abe, Harue Tada, Satoshi Morita, Akira Kakizuka, Nagahisa Yoshimura and Akitaka Tsujikawa
Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Kyoto University - Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto University - Department of Ophthalmology and Visual Sciences and Kyoto University - Department of Ophthalmology and Visual Sciences
Downloads 80 (812,480)

Abstract:

Loading...

neuroprotection; central retinal artery occlusion; first-inhumans clinical trial; best-corrected visual acuity

Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial

Number of pages: 40 Posted: 08 Apr 2019
Hanako Ikeda, Yuki Muraoka, Masayuki Hata, Eriko Sumi, Takafumi Ikeda, Takayuki Nakagawa, Hiroyasu Abe, Harue Tada, Satoshi Morita, Akira Kakizuka, Nagahisa Yoshimura and Akitaka Tsujikawa
Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Kyoto University - Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto University - Department of Ophthalmology and Visual Sciences and Kyoto University - Department of Ophthalmology and Visual Sciences
Downloads 75 (848,302)
Citation 1

Abstract:

Loading...

neuroprotection; central retinal artery occlusion; first-inhumans clinical trial; best-corrected visual acuity

Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial

Number of pages: 40 Posted: 13 Dec 2018
Hanako Ikeda, Yuki Muraoka, Masayuki Hata, Eriko Sumi, Takafumi Ikeda, Takayuki Nakagawa, Hiroyasu Abe, Harue Tada, Satoshi Morita, Akira Kakizuka, Nagahisa Yoshimura and Akitaka Tsujikawa
Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Department of Ophthalmology and Visual Sciences, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Institute for Advancement of Clinical and Translational Science, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Kyoto University - Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto University - Department of Ophthalmology and Visual Sciences and Kyoto University - Department of Ophthalmology and Visual Sciences
Downloads 55 (1,027,773)

Abstract:

Loading...

2.

Recombinant Human Fibroblast Growth Factor-2 Treatment to Prevent Femoral Head Collapse in Patients With Osteonecrosis of the Femoral Head: Trion, a Single-Arm, Historical Control, Multicenter, Phase II Trial

Number of pages: 35 Posted: 22 Mar 2021
Yutaka Kuroda, Takeyuki Tanaka, Takaki Miyagawa, Hidetoshi Hamada, Hiroyasu Abe, Toshiko Ito-Ihara, Ryuta Asada, Yusuke Fujimoto, Daisuke Takahashi, Tomonori Tetsunaga, Ayumi Kaneuji, Michiaki Takagi, Yutaka Inaba, Satoshi Morita, Nobuhiko Sugano, Sakae Tanaka, Shuichi Matsuda, Haruhiko Akiyama and TRION Collaborators
Kyoto University - Department of Orthopaedic Surgery, University of Tokyo - Department of Orthopaedic Surgery, Gifu University - Department of Orthopaedic Surgery, Osaka Universith - Department of Orthopaedic Surgery, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Kyoto Prefectural University of Medicine - The Clinical and Translational Research Center, Gifu University - Innovative and Clinical Research Promotion Center, Kagoshima University - Department of Medical Joint Materials, Hokkaido University - Department of Orthopaedic Surgery, Okayama University - Department of Orthopaedic Surgery, Kanazawa Medical University - Department of Orthopaedic Surgery, Yamagata University - Department of Orthopaedic Surgery, Yokohama City University - Department of Orthopaedic Surgery, Kyoto University - Department of Biomedical Statistics and Bioinformatics, The University of Osaka - Department of Orthopaedic Medical Engineering, University of Tokyo - Department of Orthopaedic Surgery and Spinal Surgery, Kyoto University - Department of Orthopaedic Surgery, Gifu University - Department of Orthopedic Surgery and Independent
Downloads 64 (924,743)

Abstract:

Loading...

Osteonecrosis; Femoral head; Hip; Core decompression; Growth factor; FGF; Regenerative medicine

3.

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

Number of pages: 51 Posted: 06 Nov 2018
Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Naoto Morikawa, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi and Makoto Maemondo
Kanagawa Cancer Center, Miyagi Cancer Center Research Institute, St. Marianna University - School of Medicine, Miyagi Cancer Center Research Institute, Sendai Kousei Hospital, Chiba University - Department of Respirology, Ishikawa Prefectural Central Hospital, Saitama University - Saitama Medical University International Medical Center, Hiroshima University - Hiroshima University Hospital, Fukujuji Hospital, Saiseikai Utsunomiya Hospital, Nippon Medical School, Kurume University, Saitama Cancer Center, Shimane University, National Hospital Organization (NHO) - Asahikawa Medical Center, Iwate Medical University, Aichi Hospital - Aichi Cancer Center, Niigata University, Suita Municipal Hospital, Jichi Medical University, Furukawa Seiryo Hospital, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Saitama University - Saitama Medical University International Medical Center and Iwate Medical University - School of Medicine
Downloads 57 (989,921)

Abstract:

Loading...

4.

Overall Survival Analysis of Bevacizumab Plus Erlotinib for Advanced EGFR-Mutant Metastatic NSCLC

Number of pages: 37 Posted: 05 Feb 2021
Yosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Masahiro Seike, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi and Makoto Maemondo
Sendai Kousei Hospital, Miyagi Cancer Center Research Institute, Kanagawa Cancer Center, St. Marianna University - School of Medicine, Miyagi Cancer Center Research Institute, Sendai Kousei Hospital, Chiba University - Department of Respirology, Ishikawa Prefectural Central Hospital, Saitama University - Saitama Medical University International Medical Center, Hiroshima University - Hiroshima University Hospital, Fukujuji Hospital, Saiseikai Utsunomiya Hospital, Nippon Medical School - Department of Pulmonary Medicine and Oncology, Kurume University, Saitama Cancer Center, Shimane University, National Hospital Organization (NHO) - Asahikawa Medical Center, Iwate Medical University - School of Medicine, Aichi Hospital - Aichi Cancer Center, Niigata University - Medical and Dental Hospital, Suita Municipal Hospital, Jichi Medical University, Tohoku University, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Saitama University - Saitama Medical University International Medical Center and Iwate Medical University - School of Medicine
Downloads 41 (1,183,237)

Abstract:

Loading...

5.

Proton Pump Inhibitor Use and the Efficacy of Capecitabine and Fluorouracil in Metastatic Colorectal Cancer: A Post Hoc Analysis of the AXEPT Randomised Phase III Trial

Number of pages: 27 Posted: 02 Nov 2020
Sun Young Kim, Ji Sung Lee, Junho Kang, Satoshi Morita, Young Suk Park, Junichi Sakamoto, Kei Muro, Rui-Hua Xu and Tae Won Kim
University of Ulsan, University of Ulsan - Clinical Research Center, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Sungkyunkwan University - Department of Medicine, Tokai Central Hospital, Aichi Cancer Center, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China and University of Ulsan - Department of Oncology
Downloads 41 (1,183,237)

Abstract:

Loading...

proton pump inhibitor, capecitabine, colorectal cancer